H.C. Wainwright analyst Joseph Pantginis downgraded VYNE Therapeutics (VYNE) to Neutral from Buy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYNE:
- Why Is VYNE Therapeutics Stock (VYNE) Down 70% Today?
- VYNE Therapeutics Ends Phase 2b Trial for Repibresib
- VYNE says Phase 2B trial with repibresib gel did not meet primary endpoint
- Promising Developments in VYNE Therapeutics’ Repibresib Gel for Nonsegmental Vitiligo Drive Buy Rating
- Promising Potential of VYNE Therapeutics’ Repibresib Gel in Phase IIb Study